modelOxymetazoline
Extends from Pharmacolibrary.Drugs.ATC.D.D11AX27.
Information
| name: | Oxymetazoline | |
| ATC code: | D11AX27 | route: | topical |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1.6 | L |
| clearance: | 30 | L/h |
| other parameters in model implementation | ||
Oxymetazoline is an imidazoline derivative acting as a selective alpha-1 adrenergic receptor agonist and partial alpha-2 agonist, used primarily as a topical decongestant for nasal congestion and, more recently, in topical creams for rosacea and eye drops for redness. It is approved for current clinical use as a nasal spray, ophthalmic solution, and topical dermatological preparation.
Pharmacokinetics
Pharmacokinetic parameters estimated for a typical adult after topical (cutaneous) administration; no specific published human PK data found for this cutaneous route. Values are estimated from related nasal/ophthalmic human data and animal data, extrapolated for cutaneous application.
References
Kuang, AW, et al., & Ahluwalia, G (2018). Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. Journal of drugs in dermatology : JDD 17(2) 213–220. PUBMED:https://pubmed.ncbi.nlm.nih.gov/29462230
Cartabuke, R, et al., & Jatana, KR (2021). Topical Nasal Decongestant Oxymetazoline: Safety Considerations for Perioperative Pediatric Use. Pediatrics 148(5) –. DOI:10.1542/peds.2021-054271 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34607935
Cartabuke, RS, et al., & Tobias, JD (2019). Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. The Laryngoscope 129(12) 2775–2781. DOI:10.1002/lary.27760 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30786035
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)